Schizophrenia Research and Treatment / 2018 / Article / Tab 2

Research Article

Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana

Table 2

MetS among psychotic-treated and treatment-naïve studied subjects.

VariablesTotalPsychotic-treatedTreatment-naïve
n=348n=236n=112cOR (95 CI)p-value

Met / NCEP/ATP III
075(21.6)26(11.0)49(43.8)1
1136(39.1)93(39.4)43(38.4)4.1(2.2-7.4)0.0013
288(25.2)75(31.8)13(11.6)10.9(5.1-23.2)<0.0001
≥349(14.1)42(17.8)7(6.2)11.3(4.5-47.6)0.0001
Met / IDF
047(13.5)16(6.7)31(27.7)1
1123(35.3)71(30.3)52(46.4)2.7(1.3 -5.3)0.006
296(27.6)78(32.7)18(16.1)8.4(3.8-18.5)<0.0001
≥382(23.6)71(30.3)11(9.8)12.5(5.2-30.0)<0.0001
Met / WHO
065(18.7)20(8.5)45(40.2)1
1122(35.1)75(31.8)47(42.0)3.6(1.9-6.8)<0.0001
290(25.9)79(33.5)11(9.8)16.2(7.1-36.8)<0.0001
≥371(20.4)62(26.2)9(8.0)15.5(6.5-37.2)<0.0001

NCEP ATP III: National Cholesterol Education Program, Adult Treatment Panel III; IDF: International Diabetes Federation; WHO: World Health Organization; MetS: metabolic syndrome; cOR: crude odds ratio; CI: confidence interval.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.